New emerging targets in cancer immunotherapy: the role of GITR.
GITR
cancer
immunotherapy
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
03
2020
revised:
15
05
2020
accepted:
19
06
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
20
7
2021
Statut:
ppublish
Résumé
In the last decade, immunotherapies have revolutionised anticancer treatment. However, there is still a number of patients that do not respond or acquire resistance to these treatments. Despite several efforts to combine immunotherapy with other strategies like chemotherapy, or other immunotherapy, there is an 'urgent' need to better understand the immune landscape of the tumour microenvironment. New promising approaches, in addition to blocking co-inhibitory pathways, such those cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 mediated, consist of activating co-stimulatory pathways to enhance antitumour immune responses. Among several new targets, glucocorticoid-induced TNFR-related gene (GITR) activation can promote effector T-cell function and inhibit regulatory T-cell (Treg) function. Preclinical data on GITR-agonist monoclonal antibodies (mAbs) demonstrated antitumour activity in vitro and in vivo enhancing CD8
Identifiants
pubmed: 32817129
pii: S2059-7029(20)32775-7
doi: 10.1136/esmoopen-2020-000738
pmc: PMC7451269
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Glucocorticoid-Induced TNFR-Related Protein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e000738Informations de copyright
© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: LDM reports personal fees from Roche, personal fees from Pfizer, personal fees from Ipsen, personal fees from Eli Lilly, personal fees from Novartis, personal fees from Takeda, personal fees from MSD, personal fees from Genomic Health, personal fees from Celgene, personal fees from Seattle Genetics, outside the submitted work.
Références
Sci Rep. 2019 Apr 3;9(1):5562
pubmed: 30944344
Cancer Sci. 2009 Jun;100(6):1112-7
pubmed: 19514119
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
Nat Med. 2019 May;25(5):759-766
pubmed: 31036879
J Transl Med. 2014 Feb 07;12:36
pubmed: 24502656
J Immunol. 2015 Nov 15;195(10):4721-9
pubmed: 26423152
Nat Immunol. 2002 Feb;3(2):135-42
pubmed: 11812990
J Immunother Cancer. 2014 Apr 15;2:7
pubmed: 24855562
Blood. 2008 Nov 1;112(9):3735-43
pubmed: 18689545
J Immunol. 2010 Dec 15;185(12):7223-34
pubmed: 21076066
Clin Cancer Res. 2017 Jul 1;23(13):3416-3427
pubmed: 28069723
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):641-5
pubmed: 18178614
J Immunol. 2004 Oct 15;173(8):5008-20
pubmed: 15470044
Cytokine Growth Factor Rev. 2014 Apr;25(2):91-106
pubmed: 24484736
JAMA Oncol. 2019 Nov 7;:1-8
pubmed: 31697308
Adv Exp Med Biol. 2009;647:156-73
pubmed: 19760073
J Gastroenterol Hepatol. 2013 Sep;28(9):1555-64
pubmed: 23517245
Front Immunol. 2018 Sep 20;9:2170
pubmed: 30294332
Cancer Res. 2017 Mar 1;77(5):1108-1118
pubmed: 28122327
J Exp Med. 2005 Oct 3;202(7):885-91
pubmed: 16186187
Cancer Res. 2008 Jul 15;68(14):5948-54
pubmed: 18632650
J Immunother Cancer. 2018 Sep 25;6(1):93
pubmed: 30253804
J Immunol. 2012 Jun 15;188(12):5915-23
pubmed: 22581858
Expert Opin Ther Targets. 2018 Sep;22(9):783-797
pubmed: 30107134
Clin Cancer Res. 2019 Nov 1;25(21):6501-6510
pubmed: 31358539
Blood. 2006 May 1;107(9):3617-23
pubmed: 16397134
Eur J Cancer. 2016 Nov;67:1-10
pubmed: 27591414
J Immunother Cancer. 2018 Nov 6;6(Suppl 1):115
pubmed: 30400822
Cancer Immunol Res. 2018 Oct;6(10):1199-1211
pubmed: 30154083
PLoS One. 2013 Sep 10;8(9):e73610
pubmed: 24039998
Hepatology. 2013 Jan;57(1):183-94
pubmed: 22911397
Cancer Immunol Immunother. 2010 Sep;59(9):1367-77
pubmed: 20480365
J Immunol. 2006 Jun 1;176(11):6434-42
pubmed: 16709800
Nat Med. 2015 Sep;21(9):1010-7
pubmed: 26280119
Cancer Res. 2006 May 1;66(9):4904-12
pubmed: 16651447
Cancer Immunol Res. 2013 Nov;1(5):320-31
pubmed: 24416730
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cancer Immunol Res. 2014 May;2(5):448-58
pubmed: 24795357
J Immunother. 2010 Feb-Mar;33(2):136-45
pubmed: 20145549
Sci Immunol. 2018 Nov 2;3(29):
pubmed: 30389797
Tumour Biol. 2015 May;36(5):3727-34
pubmed: 25563193
Cancer Res. 2007 Aug 1;67(15):7477-86
pubmed: 17671218
PLoS One. 2010 May 03;5(5):e10436
pubmed: 20454651
Immunol Lett. 2020 Jun;222:73-79
pubmed: 32259529
Autoimmun Rev. 2015 Feb;14(2):117-26
pubmed: 25449679
Immunity. 2002 Feb;16(2):311-23
pubmed: 11869690
Clin Cancer Res. 2010 May 15;16(10):2781-91
pubmed: 20460483